Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor

The Company Will Begin Hiring A Sales Force

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.

Team building
Bristol is laying the foundation for a new launch • Source: Alamy

Bristol Myers Squibb Company is already laying the commercial groundwork for the launch of its potential first-in-class TYK2 inhibitor deucravacitinib for psoriasis even though a US approval is at least a year away. The company said it will begin hiring a sales force in the second half of the year as it plans to make a blockbuster-sized splash into a new therapy area dominated by experienced rivals. The company has already established a medical team experienced in dermatology.

"This is a new area for BMS, and thus we've been engaged in a significant capability build to ensure that...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immunological

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Sanofi/Regeneron’s Dupixent: A First For COPD, But Not The Last

 
• By Jessica Merrill

The IL-4/13 inhibitor was approved in the US for COPD, a blockbuster-sized indication, but the commercial ramp could take time and several competitors are on its heels.

Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1

 
• By Saba Afreen

As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.